Promega builds plant to produce regulated products
Including sample preparation systems and reagents
The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.
‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.
Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.
Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
Manufacturing
Clariant opens first US pharmaceutical-grade PEG excipient manufacturing site in Texas
Clariant has expanded its Clear Lake facility in Texas to produce GMP-compliant pharmaceutical-grade polyethylene glycol excipients, marking its first US-based manufacturing site for the products and strengthening supply chain resilience for North American and Latin American pharma customers
Design & Build
ESTEVE CDMO expands spray drying and high-potency containment capacity at Girona facility
ESTEVE CDMO has announced plans to add a 3000-square-metre production unit at its Celrà site in Spain to house additional spray drying equipment and high-potency containment suites, with the first new GEA spray dryer due online in Q1 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026